Operating Expenses
Other Expense Recapitalization Of Common Stock
Polaryx Therapeutics, Inc. Other Expense Recapitalization Of Common Stock remained flat by 0.0% to $6.50M in Q4 2024 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryCapital Allocation
SignalLower is better
VolatilityVolatile
First reportedQ1 2024
Last reportedQ4 2024Mar 24, 2026
How to read this metric
An increase signals significant corporate restructuring or equity adjustments, which may impact shareholder dilution.
Detailed definition
This metric represents costs associated with the restructuring of the company's equity or capital base. It captures non-...
Peer comparison
Recapitalization costs vary widely based on the frequency of corporate financing events and equity restructuring.
Metric ID:
operating_expenses_other_expense_recapitalization_of_com_e25534Historical Data
1 years
| FY'24 | |
|---|---|
| Value | $26.00M |
Other Expense Recapitalization Of Common Stock at Other Companies
Frequently Asked Questions
- What is Polaryx Therapeutics, Inc. 's other expense recapitalization of common stock?
- Polaryx Therapeutics, Inc. (PLYX) reported other expense recapitalization of common stock of $6.50M in Q4 2024.
- What does other expense recapitalization of common stock mean?
- Costs related to changing the company's capital or share structure.